Dear Sir, Arterial hypertension is a most important complication for hemodialysis patients treated with recombinant human erythropoietin (rHuEPO), that may develop hypertensive encephalopathy with seizures. It is generally thought that the autonomic nervous system has correlation to such hypertension. However, the pathophysiological change of its system during rHuEPO therapy is unclear. Recently, Jandeleit et al. [1] reported that the autonomic nervous system activity was increased in rHuEPO therapy by measurement of plasma noradrenaline levels and stimulation of angiotensin II in hemodialysis patients. In this study, we measured plasma noradrenaline levels and dopamine-ß-hy-droxylase (DBH) activity to investigate a reaction of the sympathetic nervous system on hemodinamic changes during rHuEPO therapy. Eleven patients (mean age 55 ± 4 years; 4 male and 7 female) received regular hemodialysis 3 times a week, with the diagnosis of chronic glomerulonephitis in 9 patients and nephritis due to toxemia of pregnancy in 2. They had all normal arterial blood pressure according to WHO criteria before rHuEPO therapy. rHuEPO was administered at a dose of 48 U/kg body weight 3 times a week for 8 weeks. Plasma noradrenaline levels and DBH activity were determined before therapy and at 4 and 8 weeks after the therapy. Anemia was corrected by rHuEPO therapy. Mean hematocrit value significantly increased from 20.4 ± 0.8% (before therapy) to 26.8 ± 0.8% (at 8 weeks). Mean values for mean arterial blood pressure remained unchanged throughout the 8 weeks, i.e., 89.6 ± 2.8 mm Hg before therapy, 88.7 ± 4.1 mm Hg at 4 weeks and 89.2 ± 3.2 mm Hg at 8 weeks. Plasma noradrenaline levels and DBH activity before therapy and 4 and 8 weeks after the therapy were as follows: noradrenaline 0.3 84 ± 0.049, 0.328 ± 0.042 and 0.364 ± 0.045 ng/ml; DBH 26.4 ± 4.5, 38.9 ± 8.2 (p < 0.05) and 43.4 ± 8.6
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